Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A (2019) ISAR-REACT 5 trial Investigators. Ticagrelor or Prasugrel in patients with acute coronary syndromes. N Engl J Med 381(16):1524–1534. https://doi.org/10.1056/NEJMoa1908973Epub 2019 Sep 1.PMID: 31475799

Article  PubMed  Google Scholar 

Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575.PMID

Article  PubMed  Google Scholar 

Kubica J, Jaguszewski M (2019) ISAR-REACT5-What Havewe learned?Cardiol. J 26(5):427–428. 105603/CJ.a2019.0090, indexed in Pubmed:31536136

Google Scholar 

Arslan F, Damman P, Zwart B, Appelman Y, Voskuil M, de Vos A, van Royen N, Jukema JW, Waalewijn R, Hermanides RS, Woudstra P, Ten Cate T, Lemkes JS, Vink MA, Balder W, van der Wielen MLJ, Vlaar PJ, van der Heijden DJ, Assa S, van ‘t Hof AW, Ten Berg JM (2021 Jul) 2020 ESC guidelines on acute coronary syndrome without ST-segment elevation: recommendations and critical appraisal from the Dutch ACS and interventional cardiology working groups. Neth Heart J 7. https://doi.org/10.1007/s12471-021-01593-4

Kubica J, Jaguszewski M, Ostrowska M, Adamski P (2020) Creative scientific dispute — different points of view on the protocol and execution of the ISAR-REACT 5 trial. Med Res J 5(1):41–45. https://doi.org/10.5603/MRJ.a2020.0008

Article  Google Scholar 

Angoulvant D, Sabouret P, Savage MP NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs. 2021 Mar 6. https://doi.org/10.1007/s40256-021-00471-z

Crea F, Thiele H, Sibbing D, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Siontis GCM, Barbato E, Collet JP, Giannitsis E, Hamm CW, Böhm M, Cornel JH, Ferreiro JL, Frey N, Huber K, Kubica J, Navarese EP, Mehran R, Morais J, Storey RF, Valgimigli M, Vranckx P, James S (2021 Jun) Debate: Prasugrel rather than Ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. Eur Heart J 10:ehab277. https://doi.org/10.1093/eurheartj/ehab277

Navarese EP, Khan SU, Kołodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S (2020) Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation 142:150–160. https://doi.org/10.1161/CIRCULATIONAHA.120.046786

Article  CAS  PubMed  PubMed Central  Google Scholar 

Umińska JM, Skrzypek M, Ostrowska M, Adamski P, Kubica A, Niezgoda P, Gajda R, Gierlotka M, Hudzik B, Kuliczkowski W, Gorog DA, Gurbel PA, Siller-Matula J, Szarpak Ł, Savage M, Skonieczny G, Tantry U, Trzeciak P, Navarese EP, Kubica J, Gąsior M (2025 Jul) One-Year clinical outcomes in patients with acute coronary syndrome treated with clopidogrel versus Prasugrel versus ticagrelor: results of the Polish registry of acute coronary syndromes (PL-ACS). Kardiol Pol 29. https://doi.org/10.33963/v.phj.107718Epub ahead of print. PMID: 40728473

Wöhrle J, Seeger J, Lahu S, Mayer K, Bernlochner I, Gewalt S, Menichelli M, Witzenbichler B, Hochholzer W, Sibbing D, Cassese S, Angiolillo DJ, Hemetsberger R, Valina C, Kufner S, Xhepa E, Hapfelmeier A, Sager HB, Joner M, Richardt G, Laugwitz KL, Neumann FJ, Schunkert H, Schüpke S, Kastrati A, Ndrepepa G (2021) Ticagrelor or Prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. JACC Cardiovasc Interv 14(17):1857–1866. https://doi.org/10.1016/j.jcin.2021.06.028Epub 2021 Aug 23. PMID: 34446390

Article  PubMed  Google Scholar 

Koshy AN, Giustino G, Sartori S, Kyaw H, Yadav M, Zhang Z, Hooda A, Farooq A, Krishnamoorthy P, Sweeny JM, Khera S, Serrao GW, Sharma R, Suleman J, Dangas G, Kini AS, Mehran R, Sharma SK (2022) Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention. JACC Cardiovasc Interv. ;15(22):2270–2280. https://doi.org/10.1016/j.jcin.2022.09.021. PMID: 36423970

Ruiz-Nodar JM, Esteve-Pastor MA, Rivera-Caravaca JM, Sandín M, Lozano T, Vicente-Ibarra N, Orenes-Piñero E, Macías MJ, Pernías V, Carrillo L, Candela E, Veliz A, Tello-Montoliu A, Martínez Martínez JG, Marín F (2020) One-year efficacy and safety of Prasugrel and Ticagrelor in patients with acute coronary syndromes: results from a prospective and multicentre ACHILLES registry. Br J Clin Pharmacol 86(6):1052–1061. https://doi.org/10.1111/bcp.14213Epub 2020 Feb 3. PMID: 31912949; PMCID: PMC7256120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsai ML, Lin Y, Chen DY, Lin MS, Wang CY, Hsieh IC, Yang NI, Hung MJ, Chen TH (2024) Ticagrelor versus Adjusted-Dose Prasugrel in acute coronary syndrome with percutaneous coronary intervention. Clin Pharmacol Ther 116(3):747–756. https://doi.org/10.1002/cpt.3209Epub 2024 Feb 19. PMID: 38369974

Article  CAS  PubMed  Google Scholar 

Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van’t Hof JR, Rajpurohit A, Farley JF (2023) Comparative effectiveness of Ticagrelor, Prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: A propensity Score-Matched cohort study. Clin Pharmacol Ther 113(2):401–411 Epub 2022 Dec 13. PMID: 36399019; PMCID: PMC9877194

Article  CAS  PubMed  Google Scholar 

Venetsanos D, Träff E, Erlinge D, Hagström E, Nilsson J, Desta L, Lindahl B, Mellbin L, Omerovic E, Szummer KE, Zwackman S, Jernberg T, Alfredsson J (2021) Prasugrel versus Ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart 107(14):1145–1151. https://doi.org/10.1136/heartjnl-2020-318694Epub 2021 Mar 12. PMID: 33712510; PMCID: PMC8257560

Article  PubMed  PubMed Central  Google Scholar 

Sachdeva A, Mutyala R, Mantri N, Zhu S, McNulty E, Solomon M (2023) P2Y12 inhibitors in acute coronary syndromes: A Real-World, Community-Based comparison of ischemic and bleeding outcomes. J Interv Cardiol 2023:1147352. https://doi.org/10.1155/2023/1147352PMID: 37251366; PMCID: PMC10224789

Article  PubMed  PubMed Central  Google Scholar 

Krüger N, Krefting J, Kessler T, Schmieder R, Starnecker F, Dutsch A, Graesser C, Meyer-Lindemann U, Storz T, Pugach I, Frieß C, Chen Z, Bongiovanni D, Manea I, Dreischulte T, Offenborn F, Krase P, Sager HB, Wiebe J, Kufner S, Xhepa E, Joner M, Trenkwalder T, Gueldener U, Kastrati A, Cassese S, Schunkert H, von Scheidt M (2024) DigiMed Bayern Consortium. Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care. JAMA Netw Open. ;7(12):e2448389. doi: 10.1001/jamanetworkopen.2024.48389. Erratum in: JAMA Netw Open. 2025;8(1):e2460952. https://doi.org/10.1001/jamanetworkopen.2024.60952. PMID: 39621344; PMCID: PMC11612834

Ray A, Najmi A, Khandelwal G, Jhaj R, Sadasivam B (2024) Comparative effectiveness and safety of Prasugrel and Ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis. Indian Heart J 76(2):133–135 Epub 2024 Mar 13. PMID: 38485052; PMCID: PMC11143503

Kim Y, Jeong MH, An M, Cho K, Hong Y, Kim J, Ahn Y (2023) Long-term use of clopidogrel versus Ticagrelor or Prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention. PLoS ONE 18(2):e0278993. https://doi.org/10.1371/journal.pone.0278993PMID: 36821598; PMCID: PMC9949675

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng AK, Ng PY, Ip A, Lau KK, Siu CW (2022) Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel. Stroke Vasc Neurol 7(4):310–318. https://doi.org/10.1136/svn-2021-001294Epub 2022 Mar 9. PMID: 35264399; PMCID: PMC9453842

Article  PubMed  PubMed Central  Google Scholar 

Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van’t Hof JR, Rajpurohit A, Farley JF (2023) Comparative risk of hospitalized bleeding of P2Y12 inhibitors for secondary prophylaxis in acute coronary syndrome after percutaneous coronary intervention. Clin Pharmacol Ther 113(2):412–422 Epub 2022 Dec 28. PMID: 36448257; PMCID: PMC10107606

Article  CAS  PubMed  Google Scholar 

Gierlotka M, Gasior M, Poloński L, Piekarski M, Kamiński M (2005) Projekt, załozenia metodyczne Oraz Logistyka Ogólnopolskiego Rejestru Ostrych Zespołów Wieńcowych (PL-ACS) [Project, logistics and methodology of the National registry of acute coronary Syndrome(PL-ACS)]. Kardiol Pol 62(Suppl 1):I13–21 Polish. PMID: 19810336

PubMed  Google Scholar 

Gąsior M, Tajstra M, Deja M, Gil R, Pacholewicz J, Bartuś S, Jasiński M, Gierlotka M, Cichoń R, Witkowski A, Rogowski J, Dudek D, Tobota Z, Wojakowski W, Widenka K, Milewski K, Maruszewski B, Stępińska J, Hirnle G, Legutko J, Suwalski P, Trzeciak P, Przybyłowski P, Hrapkowicz T (2025) Percutaneous coronary intervention and coronary artery bypass grafting in myocardial infarction complicated by cardiogenic shock. Kardiol Pol 83(3):305–312. https://doi.org/10.33963/v.phj.104782Epub 2025 Feb 20. PMID: 39976500

Article  PubMed  Google Scholar 

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD (2018) Executive group on behalf of the joint European society of cardiology (ESC)/American college of cardiology (ACC)/American heart association (AHA)/World heart federation (WHF) task force for the universal definition of myocardial infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 72(18):2231–2264 Epub 2018 Aug 25. PMID: 30153967

Article  PubMed  Google Scholar 

Austin PC (2008) Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. ;1(1):62 – 7. https://doi.org/10.1161/CIRCOUTCOMES.108.790634. PMID: 20031790

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007) TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. ;357(20):2001-15. https://doi.org/10.1056/NEJMoa0706482. Epub 2007 Nov 4. PMID: 17982182

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators;, Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. ;361(11):1045-57. https://doi.org/10.1056/NEJMoa0904327. Epub 2009 Aug 30. PMID: 19717846

Kubica A, Kasprzak M, Siller-Matula J, Koziński M, Pio Navarese E, Obońska K, Andruszkiewicz A, Sztuba B, Fabiszak T, Swiątkiewicz I, Paciorek P, Kubica J (2014) Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. ;742:47–54. doi: 10.1016/j.ejphar.2014.08.009. Epub 2014 Sep 6. PMID: 25199965

Pietrzykowski Ł, Kasprzak M, Michalski P, Kosobucka A, Fabiszak T, Kubica A (2022) The influence of patient expectations on adherence to treatment regimen after myocardial infarction. Patient Educ Couns 105(2):426–431. https://doi.org/10.1016/j.pec.2021.05.030Epub 2021 May 23. PMID: 34059362

Article  PubMed  Google Scholar 

Kubica A, Kosobucka A, Fabiszak T, Gorog DA, Siller-Matula JM (2019) Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin 35(2):341–349 Epub 2018 Sep 13. PMID: 30091642

Article  PubMed  Google Scholar 

Pietrzykowski Ł, Kasprzak M, Michalski P, Kosobucka A, Fabiszak T, Kubica A (2020) Therapy discontinuation after myocardial infarction. J Clin Med 9(12):4109. https://doi.org/10.3390/jcm9124109PMID: 33352811; PMCID: PMC7766090

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubica A, Obońska K, Fabiszak T, Kubica J (2016) Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin 32(8):1441–1451 Epub 2016 May 25. PMID: 27112628.s

Article  CAS  PubMed  Google Scholar